Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has issued an update.
The Financial Supervisory Authority of Norway has approved Circio’s Prospectus, paving the way for potential future share issues and bond conversions under agreements with Atlas Special Opportunities LLC and Atlas Capital Markets LLC. This approval is a strategic step for Circio, potentially enhancing its financial flexibility and supporting its ongoing development of advanced gene and cell therapy technologies, as well as its immuno-oncology initiatives.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in the development of circular RNA vector expression technology, aimed at advancing gene and cell therapies. Their proprietary circVec platform enhances RNA stability and protein expression, positioning it as a potential new standard in gene expression technology. The company also pursues an immuno-oncology program targeting RAS-mutated cancers through collaborations.
Average Trading Volume: 351,754
Current Market Cap: NOK66.39M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.